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Abstract
Objectives To estimate the frequency and characteristics of opioid
prescribing by multiple providers in Medicare and the association with
hospital admissions related to opioid use.
Design Retrospective cohort study.
Setting Database of prescription drugs and medical claims in 20%
random sample of Medicare beneficiaries in 2010.
Participants 1 808 355 Medicare beneficiaries who filled at least one
prescription for an opioid from a pharmacy in 2010.
Main outcome measures Proportion of beneficiaries who filled opioid
prescriptions from multiple providers; proportion of these prescriptions
that were concurrently supplied; adjusted rates of hospital admissions
related to opioid use associated with multiple provider prescribing.
Results Among 1 208 100 beneficiaries with an opioid prescription, 418
530 (34.6%) filled prescriptions from two providers, 171 420 (14.2%)
from three providers, and 143 344 (11.9%) from four or more providers.
Among beneficiaries with four or more opioid providers, 110 671 (77.2%)
received concurrent opioid prescriptions from multiple providers, and
the dominant provider prescribed less than half of the mean total
prescriptions per beneficiary (7.9/15.2 prescriptions). Multiple provider
prescribing was highest among beneficiaries who were also prescribed
stimulants, non-narcotic analgesics, and central nervous system,
neuromuscular, and antineoplastic drugs. Hospital admissions related
to opioid use increased with multiple provider prescribing: the annual
unadjusted rate of admission was 1.63% (95% confidence interval 1.58
to 1.67%) for beneficiaries with one provider, 2.08% (2.03% to 2.14%)
for two providers, 2.87% (2.77% to 2.97%) for three providers, and 4.83%
(4.70% to 4.96%) for four or more providers. Results were similar after
covariate adjustment.
Conclusions Concurrent opioid prescribing by multiple providers is
common in Medicare patients and is associated with higher rates of
hospital admission related to opioid use.
Introduction
Use of prescription opioids by elderly people in the United
States has grown considerably,
1-4 driven by increasing rates of
addiction,effortstoimprovetheundertreatmentofchronicpain,
5
the expansion of drug insurance to elderly people, and industry
effortstopromotetheuseofprescriptionopioids.
5 6Forexample,
the prevalence of long term use of prescription opioids among
adults above age 65 in two large US healthcare systems
increased from 5% of patients in 1997 to 9% in 2005.
3 Despite
their therapeutic value in some clinical instances (such as pain
associated with cancer and short term relief of acute pain not
responsivetonon-opioidanalgesics),growinguseofprescription
opioids has emerged as a pressing public health problem in the
US,
7 8 in part due to public misconceptions about risks of
addiction and safety.
9 10 Across Americans of all ages, deaths
from unintentional opioid overdose grew fourfold from 1999
to 2008,
11 largely because of prescription opioids.
7 12 13 Among
elderly people, prescription opioids are associated with greater
frequenciesoffracturesand
14-16safetyeventsrequiringadmission
to hospital
15 and higher all cause mortality.
15 Concerns about
misuse of prescription opioids are not only limited to the
US—the International Narcotics Control Board has advocated
that misuse of prescription opioids is an international problem,
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Research
RESEARCHas evidenced by growing rates of deaths related to opioid use
in Canada, Australia, and the United Kingdom (where the
number of deaths involving codeine and methadone nearly
doubled between 2005 and 2009).
17
Amid national concerns over opioid misuse and adverse effects
of legitimate use, the frequency with which patients obtain
opioid prescriptions from multiple healthcare providers (such
asphysicians,dentists,or,lesscommonly,physicianassistants)
rather than a single healthcare provider has received increasing
attention in the US,
18-24 not only because it might reflect the
illicit procurement of opioids by patients intentionally seeking
out multiple providers (that is, “doctor shopping”) but because
it might indicate fragmented patient care.
25-28 Although much
ofthefocusonmultipleprovideropioidprescribinghascentered
on opioid diversion (in which legally obtained opioids are
transferred from a licit to an illicit channel of distribution or
use),
18-24 the ability of patients to receive opioid prescriptions
from multiple physicians who do not or cannot communicate
with one another can lead to fragmented prescribing of opioids,
whichisparticularlyconcerningamongelderlypatientsbecause
of increased adverse events associated with opioid use
7 8 13 and
high rates of polypharmacy in this population.
29 30 Despite this
concern, however, there are no national estimates of the
frequencyofopioidprescribingbymultipleprovidersintheUS
Medicare population, the characteristics of patients and
physicians involved, and patient outcomes associated with
multipleprovideropioidprescribing.TheUSMedicareprogram
is the primary source of insurance for Americans above the age
of65andin2012insurednearly50millionAmericans,ofwhom
about 83% were above the age of 65.
Prior studies of multiple provider prescribing in the overall
population suggest that prescribing of opioids by three or more
healthcareproviderswithinayeariscommon,withratesranging
from 10% to 15% of all individuals prescribed an opioid within
ayear.
19-24Thesestudieshaveeitherbeenlimitedtostatespecific
analyses
19 22 24 or have used national prescription databases but
havenotspecificallyanalyzedthefrequencyofmultipleprovider
opioidprescribinginMedicare,havenotstudiedcharacteristics
ofpatientsandspecialtyofprovidersinvolved,havenotfocused
onelderlyanddisabledpeoplewhoareatgreatestriskofadverse
events associated with prescription opioid drugs, and, most
importantly, have not analyzed adverse outcomes associated
with multiple provider prescribing.
18 23
Usingdataontheprescriptiondrugclaimsofanationalrandom
sample of Medicare beneficiaries who filled a prescription for
anopioidfromapharmacyin2010,weestimatedthefrequency
of multiple provider prescribing of opioids to Medicare
beneficiaries,studiedthecharacteristicsofpatientsandproviders
involved, and estimated the association between multiple
providerprescribingandadmissionstohospitalrelatedtoopioid
use.
Methods
Background on the US Medicare program
The US Medicare program is the primary source of healthcare
insuranceforAmericansabovetheageof65andforindividuals
aged under 65 with specific disabilities and conditions such as
end stage renal disease requiring hemodialysis. In 2012, about
83% of Medicare’s 50 million enrollees were above the age of
65 and the remaining younger enrollees had disabilities or
specific clinical conditions as above. For each insured
beneficiary,Medicarecoversthecostsofinpatientcarethrough
Medicare Part A, the costs of outpatient care through Medicare
Part B, and the costs of prescription drug coverage through
Medicare Part D. While most Medicare enrollees receive their
insurance through traditional Medicare—a system in which
healthcare professionals and hospitals bill the US Centers for
Medicare and Medicaid Services (CMS) directly for any care
that is provided—about a quarter of Medicare enrollees receive
their insurance through Medicare Advantage insurance
(otherwise referred to as Part C). Medicare Advantage is a type
ofMedicarehealthplanofferedbyprivateinsurancecompanies
that contract with Medicare to provide beneficiaries with
inpatient, outpatient, and prescription drug coverage.
Prescription claims data used in this study
Each year, the US Centers for Medicare and Medicaid Services
processmorethanabillionprescriptiondrugclaimsforitsmore
than37millionbeneficiarieswhoreceivetheirprescriptiondrug
insurance through the Medicare Part D program. Through an
agreementwithCMS,weobtaineddataontheprescriptiondrug
claims of a 20% random sample of Medicare beneficiaries who
had Part D coverage in 2010. Because not all Medicare
beneficiaries obtain their prescription drug coverage through
the Part D program—for example, of 50.7 million Medicare
beneficiaries in 2012, 37.1 million had Part D coverage—our
sample was not representative of Medicare overall but instead
representative of the Part D population.
We identified prescription claims corresponding to an opioid
drug (complete or partial opioid agonists and combination
formulations) according to National Drug Code (see appendix
table A); formulations used for antidiarrheal and antitussive
purposeswereexcluded.Themostcommonlyprescribedopioids
were hydrocodone with acetaminophen (paracetamol) (42.9%
ofallclaims),oxycodonewithacetaminophen(11.6%),tramadol
(11.9%), oxycodone (7.4%), morphine sulfate (4.5%), and
fentanyl (4.2%). We did not have information on the indication
for which the opioid was prescribed.
Beneficiarydemographicdataincludedinformationonage,sex,
race(non-Hispanicwhite,non-Hispanicblack,Hispanic,Asian,
other including Native Americans), residence in a metropolitan
area, and zipcode. Additional data on beneficiaries included
whether or not a they received a low income subsidy at least
onemonthoftheyear(afinancialsubsidyprovidedtoqualifying
beneficiarieswithannualincomebelowagovernmentspecified
income threshold); whether or not a beneficiary received dual
insurance coverage by Medicaid and Medicare at least one
monthoftheyear(providedtoindividualswithsufficientlylow
income that allows them to qualify for combined
Medicare-Medicaidinsurancecoveragethatsubstantiallyreduces
out of pocket expenditures); and whether or not a beneficiary
received prescription coverage by Medicare Advantage versus
a traditional Part D drug plan.
Drug claims were linked to information on each individual
provider who prescribed the drugs, according to a unique
encrypted provider identifier. For each prescription, the linked
file provided information on provider type (such as physician,
dentist, physician assistant) and physician specialty. Median
household income in a beneficiary’s residential zipcode was
obtainedfromthe2010UScensus.Weincludedallbeneficiaries
who resided in the US, were continuously enrolled in Medicare
during 2010, filled at least one prescription for an opioid that
year, and had provider information for all filled opioid
prescriptions. This resulted in a sample of 1 808 355
beneficiaries, implying that among 5 214 910 Medicare
beneficiaries in the 20% sample with continuous enrollment
during 2010, 34.7% filled at least one opioid prescription.
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RESEARCHDefining prescribing of opioids by multiple
providers
We counted the number of unique opioid providers for each
beneficiary in 2010. We categorized beneficiaries into whether
they filled only one prescription for an opioid or filled two or
more prescriptions from one unique provider or two, three, or
four or more providers. Patients can fill opioid prescriptions
from more than one provider for several reasons, including a
change in the primary provider responsible for opioid
prescribing,thereceiptofanopioidprescriptionfromaprovider
covering the patient’s customary provider, prescribing by
consultant physicians or in settings such as a dentist’s office or
emergencyroom,or“doctorshopping.”
19Althoughseveralprior
studies dichotomize prescribing of controlled substances by
multiple providers into whether or not prescribing patterns
reflect “doctor shopping,” this categorization might obscure
evidence of fragmented opioid prescribing that is equally
important to consider.
Descriptive analyses
We conducted four descriptive analyses. First, we computed
thefrequencywithwhichbeneficiariesfilledopioidprescriptions
from multiple providers and described the characteristics of
those who filled prescriptions from a single provider versus
multiple providers. Second, we examined how opioid
prescriptions were divided among a beneficiary’s providers by
estimating the mean number of opioid prescriptions provided
by a beneficiary’s dominant provider versus other providers.
Third, to distinguish inappropriate prescribing from potentially
appropriate prescribing (such as filling a prescription from a
dentist after routine surgery), we estimated the proportion of
beneficiarieswhoreceivedconcurrentopioidprescriptionsfrom
twoormoreproviders.Concurrentusewasdefinedasanopioid
prescription from a second provider being filled before the
supply of an existing opioid prescription from another provider
had ended. Fourth, we analyzed the distribution of opioid
prescriptions across physician specialties and non-physician
providers (dentists, physician assistants, and others).
Multivariate analysis of factors associated
with multiple provider prescribing
We estimated a beneficiary level logistic regression model to
studybeneficiaryfactorsassociatedwithprescribingofopioids
by multiple providers. The dependent variable was a binary
outcome of whether or not a beneficiary obtained opioid
prescriptions from two or more providers in 2010. The
independentvariablesincludedbeneficiary’sage,sex,race,and
binary indicators for Medicare-Medicaid dual eligibility and
low income subsidy for at least one month during the year, a
binary indicator for Medicare Advantage (MA) rather than a
stand-alone Part D drug plan for at least one month, a binary
indicator for metropolitan residence, indicator variables for
prescription therapeutic classes other than opioids (identified
according to the NDC), median income of zipcode area, and
indicatorsforthecorebasedstatisticalareaofthebeneficiaries.
Dual eligibility for Medicare-Medicaid and receipt of low
income subsidy were included to assess whether fragmentation
of opioid prescribing was greater in this poorer population with
characteristically high utilization of healthcare resources and
fragmented care.
31 32 Coverage by a Medicare Advantage plan
was included as an explanatory variable as these plans might
offer more integrated care—and therefore lower the likelihood
ofopioidprescribingfrommultipleproviders—thantraditional
Medicareenrollees.
33-36Finally,weincludedanindicatorvariable
for whether a beneficiary’s state had a prescription drug
monitoring program in effect in 2010. Although the evidence
is mixed, several studies suggest that state programs for
monitoring prescription drugs are associated with lower rates
of opioid diversion and prescribing by multiple providers.
37-41
Hospital admissions related to opioid use
To study adverse outcomes associated with prescribing of
opioids by multiple providers, we estimated a beneficiary level
logisticregressionoftheassociationbetweenmultipleprovider
prescribing and any admission related to opioid use in 2010.
Admissions were identified from the linked Medicare provider
analysisandreviewfile—adatafileobtainedthroughagreement
with the Centers for Medicare and Medicaid Services—which
includes claims for all inpatient services used by traditional
Medicare beneficiaries. Based on prior studies, admissions
related to opioid use were identified from inpatient diagnosis
codesforopioiddrugdependence,opioidpoisoning,respiratory
failure, drug induced mental disorders (including alternation of
consciousness and hallucinations), constipation, and malaise,
fatigue, or lethargy.
42-44
We focused on traditional Medicare beneficiaries with 12
months of enrollment (n=1 157 423) because data on inpatient
admissions are not available for enrollees in the Medicare
Advantage(thatis,non-traditionalMedicare)plan.Theprimary
explanatory variables of interest included indicator variables
for whether a beneficiary received opioid prescriptions from
one, two, three, or four or more providers. In addition to
adjusting for beneficiary age, sex, race, eligibility for
Medicare-Medicaiddualandlowincomesubsidy,andindicator
variables for prescription therapeutic classes, we also adjusted
for the total number of opioid prescriptions a beneficiary
received. Among patients receiving the same number of opioid
prescriptionsannually,wethereforeestimatedwhetherpatients
receivingprescriptionsfrommultipleprovidersweremorelikely
to be admitted for a complication related to opioid use. We
reportedtheadjustedpercentageofbeneficiarieswithanopioid
related admission according to the number of unique opioid
providers.
All analyses were conducted with Stata version 12 (StataCorp,
College Station, TX). The 95% confidence interval around
reported means reflects 0.025 in each tail or P≤0.05.
Results
Our sample included 1 808 355 beneficiaries with at least one
filled prescription for an opioid in 2010. Prescribing of opioids
by multiple providers was common: 418 530 (23.1%)
beneficiariesfilledopioidprescriptionsfromtwoproviders,171
420(9.5%)fromthreeproviders,and143344(7.9%)fromfour
or more providers (table 1⇓). Among 1 208 100 beneficiaries
who filled more than one opioid prescription, 39.3% filled
prescriptions from one provider, 34.6% from two providers,
14.2% from three providers, and 11.9% from four or more
providers.
The mean number of opioid prescriptions per beneficiary
increased substantially with multiple providers. Beneficiaries
with opioid prescriptions from four or more providers had on
average 15.2 opioid prescriptions (SD 9.8), compared with 7.1
(SD 7.1) and 10.1 (SD 7.9) among beneficiaries filling opioid
prescriptions from two and three providers, respectively. More
opioid prescriptions were filled by women (1 144 080/1 808
355;63.3%),withlittlechangeinthispercentageasbeneficiaries
receivedopioidprescriptionsfrommoreproviders.Beneficiaries
who filled opioid prescriptions from a larger number of
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RESEARCHproviders were also younger. For example, 16.3% (23 343/143
344) of beneficiaries filling opioid prescriptions from four or
more providers were under age 45 compared with 6.5% (26
982/418 530) and 8.9% (15 283/171 420) among beneficiaries
filling opioid prescriptions from two and three providers,
respectively (P<0.001 for test of joint significance). The
proportion of beneficiaries filling an opioid prescription who
were non-Hispanic black increased slightly as beneficiaries
filled opioid prescriptions from more providers; 17.2% (24
580/143 344) of beneficiaries who filled opioid prescriptions
fromfourormoreproviderswerenon-Hispanicblackcompared
with 12.7% (52 927/418 530) and 14.2% (24 257/171 420) of
beneficiarieswhofilledopioidprescriptionsfromtwoandthree
providers, respectively (P<0.001 for test of joint significance).
Dual eligible beneficiaries comprised a larger proportion of
beneficiaries who filled opioid prescriptions from four or more
providers(85807/143344;59.9%)thanbeneficiarieswhofilled
opioid prescriptions from only one provider (201 138/474 806;
42.4%) (P<0.001).
The proportion of total prescriptions provided by a single
dominant provider declined as beneficiaries received
prescriptions from multiple providers (table 2⇓). Beneficiaries
who filled opioid prescriptions from two providers had an
average of 5.56 prescriptions (95% confidence interval 5.54 to
5.58)providedbythedominantproviderand1.57(1.57to1.58)
prescriptions provided by the second most dominant provider.
In contrast, among beneficiaries who filled prescriptions from
four or more providers, the dominant provider accounted for
7.93 prescriptions per beneficiary (7.89 to 7.97), less than half
of the mean total prescriptions per beneficiary in this group
(15.2).
A substantial proportion of beneficiaries received concurrent
opioid prescriptions from two or more providers. For example,
among 418 530 beneficiaries with opioid prescriptions from
twoproviders,120263(28.7%,95%confidenceinterval28.6%
to28.9%)receivedconcurrentprescriptionsfrombothproviders.
The frequency of concurrent prescribing increased with the
numberofproviders.Forinstance,among171420beneficiaries
with opioid prescriptions from three providers, 89 961 (52.5%,
52.2% to 52.7%) received concurrent prescriptions from two
or more of those providers. Furthermore, among 143 344
beneficiaries with opioid prescriptions from four or more
providers,110671(77.2%,76.9%to77.4%)receivedconcurrent
prescriptions from two or more of those providers.
Most beneficiaries with multiple opioid providers received
prescriptions from internists or family practitioners, followed
by surgeons, emergency medicine physicians, and physician
assistants (appendix table B). Although anesthesiologists and
pain medicine specialists were an uncommon source of opioid
prescriptions for beneficiaries with only one provider (11
003/474 806; 2.3%), the mean number of prescriptions per
beneficiary was highest among this group of physicians (12.3
prescriptions, 95% confidence interval 12.1 to 12.5).
Factors associated with multiple provider
prescribing
Multiple provider prescribing was more common among
younger beneficiaries in both unadjusted and adjusted analyses
(table 3⇓). For instance, the adjusted odds ratio for filling an
opioid prescription from multiple providers was 3.35 (95%
confidenceinterval3.28to3.42)amongbeneficiariesagedunder
45(referencegroupage≥85)comparedwith1.55(1.53to1.57)
among those aged 65-74.
Non-Hispanicblackpatients,Hispanics,andthoseofotherraces
were more likely to fill opioid prescriptions from multiple
providers compared with non-Hispanic white patients. For
example,theadjustedoddsratiooffillinganopioidprescription
frommultipleproviderswas1.20(95%confidenceinterval1.18
to 1.22) among non-Hispanic black patients compared with
non-Hispanic white patients. Women were slightly less likely
than men to fill opioid prescriptions from multiple providers.
Beneficiarieswholivedinnon-metropolitanareas,receivedlow
income subsidies, or were dually eligible for Medicare and
Medicaid were also generally less likely to fill opioid
prescriptions from multiple providers.
Beneficiaries filling prescriptions for antineoplastic drugs,
stimulants, other central nervous system drugs, neuromuscular
drugs, and non-narcotic analgesic drugs were more likely to fill
opioid prescriptions from multiple providers than beneficiaries
who did not use drugs in these classes. For example, the odds
ratio for filling opioid prescriptions from multiple providers
was1.28(95%confidenceinterval1.27to1.29)forbeneficiaries
who filled at least one prescription for a neuromuscular drug
compared with those who did not.
Beneficiaries enrolled in Medicare Advantage plans were
slightly more likely than beneficiaries enrolled in traditional
PartDplanstofillopioidprescriptionsfrommultipleproviders.
The association between state prescription drug monitoring
plans and filling opioid prescriptions from multiple providers
was not significant.
Opioid related admission to hospital
Multiple provider prescribing was positively associated with
annual rates of admission to hospital related to opioid use in
both unadjusted and adjusted analyses (table 4⇓). Among 314
132 beneficiaries with one unique provider, 5111 (unadjusted
1.63%,95%confidenceinterval1.58%to1.67%)hadanopioid
related admission in 2010, compared with 5598/268 753
beneficiaries (2.08%, 2.03% to 2.14%) with two providers,
3209/111830beneficiaries(2.87%,2.77%to2.97%)withthree
providers, and 4735/98 048 beneficiaries (4.83%, 4.70% to
4.96%) with four or more providers. Statistical tests for an
increasing trend across categories were significant at P<0.01
for each comparison (for example, rates of admission among
patientswithtwovoneprovider,threevtwoproviders,andfour
or more v three providers). In adjusted analyses, results of
statistical tests for an increasing trend across categories were
again significant at P<0.01 for each comparison.
Discussion
Using prescription claims data from a national sample of US
Medicare beneficiaries in 2010, we found that concurrent
prescribingofopioidsbymultipleproviderswascommon.More
importantly, patients’ receipt of prescription opioids from
multiple providers was strongly associated with higher rates of
admissiontohospitalrelatedtoopioiduse.Forexample,among
patients utilizing the same quantity of prescribed opioid drug
over the course of a year, those who received prescription
opioidsfromfourormoreuniqueprovidershadtwicetheannual
rate of admission than those who received prescription opioids
from only one provider (3.2% v 1.6% admitted in a year).
Multipleprovideropioidprescribingwashighestamongyounger
beneficiaries, black patients, and those who filled prescriptions
forstimulants,othercentralnervoussystemdrugs,non-narcotic
analgesic drugs, neuromuscular drugs, or antineoplastic drugs.
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RESEARCHInterpretation of findings
Whilepatientsmightappropriatelyfillopioidprescriptionsfrom
multipleprovidersforreasonssuchasachangeintheirprimary
opioid provider, prescribing by a covering physician, or
prescribing in settings such as a dentist’s office or emergency
room, multiple provider prescribing might also reflect
fragmented care—whereby no specific physician is solely
responsible for a patient’s needs for opioid prescription—or
intentionaldoctorshoppingbypatients.
19Althoughpriorstudies
of multiple provider opioid prescribing have specifically
attempted to identify patterns of doctor shopping in younger
adult populations,
18-24 such prescribing among elderly
people—who comprise nearly 75% of the Medicare population
we studied, as defined by age >65—is concerning because of
increased adverse events associated with opioid use in this
population,
7 8 13 in part due to changes in drug metabolism and
excretion that occur with ageing as well as frequent
poly-pharmacy.
29 30 While guidelines recommend prescribing
of opioids by a single provider,
45 46 we found not only that
prescribing of opioids by multiple providers was common in
Medicare but that concurrent opioid prescribing by multiple
providerswasalsocommon.Multipleproviderprescribingwas
associated with more admissions related to opioid use, and,
moreover, patients prescribed opioids from multiple providers
were also often prescribed potentially inappropriate drugs for
elderly and disabled patients—for example, benzodiazepines,
antipsychotic drugs, and skeletal muscle relaxants.
29 47
Implications for healthcare professionals and
policymakers
For physicians and other healthcare professionals, our findings
not only highlight the dramatic prevalence of multiple provider
opioidprescribingamongelderlyanddisabledpeoplebut,more
importantly, show the adverse health outcomes associated with
this fragmented prescribing. Our findings reinforce the need to
educatepatientsabouttherisksassociatedwithobtainingopioid
prescriptions from multiple providers. For policymakers, our
findings suggest the potential importance of new state efforts,
such as those in Massachusetts, to provide physicians with the
ability to view online the prescription histories of their patients
in the past year. While not yet formally evaluated because of
the recent nature of these programs, such efforts to monitor
prescription drug targeted at physicians have the potential to
reducedoctorshoppingbyallowingphysicianstobettermonitor,
identify, and deal with fragmented opioid prescribing directly.
Our findings also suggest that other existing efforts to monitor
prescription drugs implemented by states—such as those
specifically designed to reduce illicit opioid diversion—should
consider expansion to identify patterns of opioid prescribing
that are not necessarily illicit but might nonetheless reflect
potentiallyharmfulfragmentedprescribing.Finally,ourresults
also suggest a potentially greater role for pharmacists to serve
as gatekeepers to prescription opioid drugs. For example,
pharmacists can use computerized databases of prescription
filling integrated into their practice to notify all providers when
a patient concurrently fills two or more prescriptions for an
opioid from multiple providers.
Strengths and weaknesses in relation to other
studies
Our study had several strengths and weaknesses. Prior studies
ofmultipleproviderprescribinghavegenerallybeenlimitedby
focusing on analyses of particular US states rather than the
nation as a whole,
19 22 24 have not studied characteristics of
patientsandprovidersinvolvedthatareassociatedwithmultiple
provider prescribing, have not focused on elderly and disabled
people (such as Medicare) who are at highest risk of
complications associated with opioid drugs, and, most
importantly, have not studied adverse patient outcomes such as
opioid related admissions to hospital associated with multiple
provider prescribing.
18 23
Nonetheless,ourstudyhadseverallimitations.First,ideallywe
would have studied a representative sample of all individuals
in the US prescribed opioids rather than those in Medicare and
been able to separately estimate the prevalence of multiple
provider prescribing across Medicare and non-Medicare
populations as well as the possibly distinct effects of multiple
providerprescribingonpatientoutcomessuchasopioidrelated
admissions. Importantly, however, our estimated rates of
multiple provider opioid prescribing were similar to rates in
other studies that were not limited to the Medicare
population.
18-24 Second, we could not definitively determine
whether multiple provider prescribing reflected appropriate
prescribing, fragmented care, or doctor shopping. While
prescribing by multiple providers can often be appropriate,
nearly a quarter of Medicare beneficiaries with more than one
opioid prescription in 2010 received prescriptions from three
or more providers, and, among these beneficiaries, nearly 64%
received concurrent opioid prescriptions from different
providers. Both findings suggest that fragmented prescribing
of opioids is common. Third, although we showed higher rates
of opioid related admissions among beneficiaries who receive
opioidsfrommultipleproviders,wecouldnotdeterminewhether
this association reflects a direct impact of fragmented opioid
prescribing on admissions or is due to selection bias among
these beneficiaries. While is important to distinguish these two
possibilities, our findings nonetheless highlight the importance
to clinicians of identifying beneficiaries who receive opioid
prescriptions from multiple providers as these individuals are
athighestriskofopioidrelatedadmissions.Fourth,ouranalysis
of adverse clinical outcomes associated with multiple provider
opioidprescribingwaslimitedtoopioidrelatedadmissionsand
did not include mortality. Finally, our analysis did not
distinguishbetweenmultipleproviderprescribingofhighversus
lowpotencyopioidsordifferingopioiddoses.Theidealmeasure
of opioid use would be to report total milligrams of morphine
equivalency, to capture not only differences in doses across
opioid prescriptions but also differences in potency of different
opioids.
Conclusions
Despite its limitations, our study suggests that concurrent
prescribing of opioids by multiple providers is common among
Medicare beneficiaries and is associated with higher rates of
hospital admissions related to use. Education of patients about
the risks of obtaining prescription opioids from multiple
providers, combined with enhancement of state efforts to
monitor prescription drugs that allow access by providers to
prescription databases at the point of care might be useful in
curbing this practice.
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RESEARCHWhat is already known on this topic
The frequency with which patients obtain opioid prescriptions from multiple healthcare providers has received increasing attention
Although opioids are associated with adverse events in elderly patients, estimates of the frequency and characteristics of multiple
provider opioid prescribing among Medicare beneficiaries are unknown, as are associated outcomes
What this study adds
In the United States, Medicare beneficiaries often receive prescriptions for opioid drugs from multiple providers; of those with four or
more opioid providers, more than three quarters receive concurrent opioid prescriptions from multiple providers
Beneficiaries receiving opioids from multiple providers are also more likely to be prescribed other drugs that have high rates of adverse
effects and misuse
Opioid prescribing by multiple providers is associated with higher rates of opioid related admissions
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RESEARCHTables
Table 1| Characteristics of Medicare beneficiaries with opioid prescription in 2010 according to number of unique opioid providers. Figures
are percentages (number) unless stated otherwise
>1 prescription 1
prescription only Entire sample ≥4 providers 3 providers 2 providers 1 provider
143 344 171 420 418 530 474 806 600 255 1 808 355 No of beneficiaries
15.2 (9.8) 10.1 (7.9) 7.1 (7.1) 7.5 (6.9) 1 (0) 6.1 (7.4) Mean (SD) No of opioid prescriptions
Age (years):
16.3 (23 343) 8.9 (15 283) 6.5 (26 982) 4.3 (20 219) 5.1 (30 371) 6.4 (116 198) <45
20.4 (29 298) 13.7 (23 462) 10.0 (41 933) 8.8 (41 947) 5.2 (30 966) 9.3 (167 606) 45-54
18.2 (26 109) 15.8 (27 030) 13.1 (54 852) 13.0 (61 670) 7.4 (44 351) 11.8 (214 012) 55-64
27.4 (39 222) 34.4 (59 030) 37.3 (156 058) 35.4 (167 888) 44.3 (265 763) 38.0 (687 961) 65-74
13.9 (19 889) 20.4 (35 012) 24.1 (100 687) 25.9 (123 123) 28.0 (167 999) 24.7 (446 710) 75-84
3.8 (5483) 6.8 (11 603) 9.1 (38 018) 12.6 (59 959) 10.1 (60 805) 9.7 (175 868) ≥85
60.1 (15.0) 65.4 (14.2) 68.1 (13.6) 70.1 (13.1) 70.5 (12.6) 68.5 (13.6) Mean (SD) age (years)
65.1 (93 243) 65.4 (112 108) 64.5 (270 104) 65.3 (309 953) 59.8 (358 672) 63.3 (1 144 080) Female
35.0 (50 101) 34.6 (59 312) 35.5 (148 426) 34.7 (164 853) 40.3 (241 583) 36.7 (664 275) Male
Race:
77.6 (111 221) 80.2 (137 535) 81.2 (339 970) 82.3 (390 740) 81.1 (486 892) 81.1 (1 466 358) Non-Hispanic white
17.2 (24 580) 14.2 (24 257) 12.7 (52 927) 11.6 (55 277) 11.1 (66 758) 12.4 (223 799) Non-Hispanic black
0.6 (903) 0.9 (1566) 1.3 (5 439) 1.5 (7 269) 2.3 (13 643) 1.6 (28 820) Asian
2.6 (3676) 2.9 (4882) 3.0 (12 460) 2.8 (13 300) 3.3 (19 706) 3.0 (54 024) Hispanic
2.1 (2964) 1.9 (3180) 1.9 (7734) 1.7 (8220) 2.2 (13 256) 2.0 (35 354) Other
Subsidy/dual eligibility status:
33.3 (47 763) 45.5 (78 048) 52.3 (218 831) 50.9 (241 517) 65.4 (392 611) 54.1 (978 770) Non-eligible for subsidy
6.8 (9774) 6.7 (11 532) 6.4 (26 746) 6.8 (32 151) 5.0 (29 726) 6.1 (109 929) Low income subsidy only
59.9 (85 807) 47.7 (81 840) 41.3 (172 953) 42.4 (201 138) 29.6 (177 918) 39.8 (719 656) Medicare-Medicaid dual eligible
30.5 (43 722) 34.3 (58 759) 35.5 (148 454) 33.7 (160 030) 39.1 (234 537) 35.7 (645 502) Medicare Advantage beneficiary
Other drug utilization:
6.4 (9203) 5.8 (9964) 5.3 (22 198) 4.9 (23 216) 4.1 (24 293) 4.9 (88 874) Antineoplastic
3.4 (4905) 2.2 (3833) 1.7 (6934) 1.4 (6828) 0.8 (4760) 1.5 (27 260) Stimulant
8.3 (11 933) 7.5 (12 882) 7.3 (30 324) 8.5 (40 519) 6.1 (36 334) 7.3 (131 992) Psychotherapeutic
71.9 (103 009) 62.0 (106 279) 53.9 (225 708) 52.7 (250 080) 36.3 (218 005) 49.9 (903 081) Central nervous system medication
67.2 (96 293) 54.4 (93 276) 44.6 (186 688) 40.7 (193 058) 25.1 (150 788) 39.8 (720 103) Neuromuscular
51.3 (73 595) 45.0 (77 195) 40.3 (168 482) 35.6 (169 158) 31.1 (186 835) 37.3 (675 265) Non-opioid analgesics
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RESEARCHTable 2| Number of opioid prescriptions supplied by each provider per beneficiary. Figures are shown with 95% confidence interval
>1 prescription
1 prescription only ≥4 providers 3 providers 2 providers 1 provider
143 344 171 420 418 530 474 806 600 255 No of beneficiaries
7.93 (7.89 to 7.97) 6.69 (6.66 to 6.72) 5.56 (5.54 to 5.58) 7.50 (7.48 to 7.52) 1 Mean No of prescriptions from dominant provider
3.05 (3.04 to 3.07) 2.16 (2.15 to 2.17) 1.57 (1.57 to 1.58) — — Mean No of prescriptions from second ranked provider
1.73 (1.72 to 1.73) 1.20 (1.20 to 1.20) — — — Mean No of prescriptions from third ranked provider
1.24 (1.24 to 1.24) — — — — Mean No of prescriptions from fourth ranked provider
2.57 (2.55 to 2.59) — — — — Mean No of prescriptions from fifth or lower ranked provider
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RESEARCHTable 3| Factors associated with prescribing of opioids by multiple providers in beneficiaries who obtained prescriptions from one or more
providers. Results are from beneficiary level logistic regression of factors associated with whether or not beneficiary received prescriptions
from multiple providers
Odds ratio (95% CI)
% (No) of beneficiaries Adjusted Unadjusted
Age (years):
3.35 (3.28 to 3.42) 3.53 (3.46 to 3.60) 76.4 (65 608/85 827) <45
2.28 (2.24 to 2.32) 2.46 (2.42 to 2.50) 69.3 (94 693/136 640) 45-54
1.73 (1.70 to 1.76) 1.91 (1.88 to 1.93) 63.7 (107 991/169 661) 55-64
1.55 (1.53 to 1.57) 1.65 (1.63 to 1.67) 60.2 (254 310/422 198) 65-74
1.32 (1.31 to 1.34) 1.38 (1.36 to 1.39) 55.8 (155 588/278 711) 75-84
Reference Reference 47.9 (55 104/115 063) ≥85
Race:
Reference Reference 60.1 (588 726/979 466) Non-Hispanic white
1.20 (1.18 to 1.22) 1.22 (1.21 to 1.24) 64.8 (101 764/157 041) Non-Hispanic black
0.77 (0.75 to 0.80) 0.72 (0.70 to 0.75) 52.1 (7 908/15 177) Asian
1.07 (1.04 to 1.09) 1.05 (1.03 to 1.07) 61.2 (21 018/34 318) Hispanic
1.07 (1.04 to 1.10) 1.12 (1.09 to 1.15) 62.8 (13 878/22 098) Other
Sex:
Reference Reference 61.0 (257 839/422 692) Male
0.98 (0.97 to 0.99) 0.98 (0.97 to 0.99) 60.5 (475 455/785 408) Female
Metropolitan area:
Reference Reference 61.4 (555 549/905 201) Yes
0.81 (0.68 to 0.97) 0.89 (0.88 to 0.90) 58.7 (177 745/302 899) No
1.03 (1.03 to 1.04) 1.02 (1.01 to 1.02) — Median household income in zipcode*
Subsidy/dual-eligible status:
Reference Reference 58.8 (344 642/586 159) Non-eligible for subsidy
0.88 (0.87 to 0.90) 1.05 (1.03 to 1.06) 59.9 (48 052/80 203) Low-income subsidy only
0.91 (0.90 to 0.91) 1.19 (1.18 to 1.20) 62.9 (340 600/541 738) Medicare-Medicaid dual eligible
Other drug utilization:
Reference Reference 60.5 (691 929/1 143 519) Anti-neoplastic agents (no)
1.17 (1.15 to 1.92) 1.16 (1.14 to 1.18) 64.1 (41 365/64 581) Anti-neoplastic agents (yes)
Reference Reference 60.5 (717 622/1 185 600) Stimulants (no)
1.04 (1.01 to 1.07) 1.50 (1.45 to 1.54) 69.7 (15 672/22 500) Stimulants (yes)
Reference Reference 61.0 (678 155/1 112 442) Psychotherapeutic/neurological agents
(no)
0.87 (0.86 to 0.89) 0.87 (0.86 to 0.88) 57.6 (55 139/95 658) Psychotherapeutic/neurological agents
(yes)
Reference Reference 57.0 (298 298/523 024) Central nervous system drugs (no)
1.10 (1.09 to 1.10) 1.31 (1.30 to 1.32) 63.5 (434 996/685 076) Central nervous system drugs (yes)
Reference Reference 55.9 (357 037/638 785) Neuromuscular agents (no)
1.28 (1.27 to 1.29) 1.54 (1.53 to 1.55) 66.1 (376 257/569 315) Neuromuscular agents (yes)
Reference Reference 57.5 (414 022/719 670) Non-narcotic analgesic (no)
1.26 (1.25 to 1.27) 1.39 (1.38 to 1.40) 65.4 (319 272/488 430) Non-narcotic analgesic (yes)
Medicare Advantage:
Reference Reference 60.5 (482 359/797 135) No
1.07 (1.06 to 1.08) 1.02 (1.02 to 1.03) 61.1 (250 935/410 965) Yes
State prescription drug monitoring program:
Reference Reference 60.9 (219 887/361 383) No
1.01 (0.99 to 1.02) 1.01 (1.00 to 1.02) 60.6 (513 407/846 717) Yes
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RESEARCHTable 3 (continued)
Odds ratio (95% CI)
% (No) of beneficiaries Adjusted Unadjusted
*Continuous rather than categorical variable. Odds ratios reflect effect of $1 increase in median zipcode household income on odds of filling opioid prescription
from multiple providers v one provider.
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RESEARCHTable 4| Unadjusted and adjusted percentage of Medicare beneficiaries with admission to hospital related to opioid use in 2010, according
to number of unique opioid providers
Percent admitted to hospital* (95% CI)
No of opioid related
admissions No of beneficiaries
No of unique opioid
providers Adjusted† Unadjusted
1.64 (1.59 to 1.69) 1.63 (1.58 to 1.67) 5111 314 132 1
1.97 (1.92 to 2.02) 2.08 (2.03 to 2.14) 5598 268 753 2
2.33 (2.25 to 2.41) 2.87 (2.77 to 2.97) 3209 111 830 3
3.24 (3.14 to 3.33) 4.83 (4.70 to 4.96) 4735 98 048 ≥4
*Rates computed for traditional Medicare beneficiaries in 2010. Admission information was not available for Medicare Advantage enrolees.
†Adjusted rates based on logistic model in which binary outcome variable was any opioid related admission in 2010. Primary explanatory variables of interest
included indicator variables for whether beneficiary received opioid prescriptions from 1, 2, 3, or ≥4 providers. Other independent variables included beneficiary
age, sex, race, binary indicators for Medicare-Medicaid dual eligibility and low income subsidy for at least one month during year, binary indicator for metropolitan
residence, indicator variables for prescription therapeutic classes other than opioids (identified according to National Drug Code), median income of zipcode area,
and indicators for core based statistical area of beneficiaries.
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